These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26356487)

  • 1. Inflammatory Characteristics of Monocytes from Pediatric Patients with Tuberous Sclerosis.
    Meyer CU; Kurlemann G; Sauter M; Wiemer-Kruel A; Hahn A; Doganci A; Birkholz J; Faber J; Gehring S; Hertzberg C; Zepp F; Knuf M
    Neuropediatrics; 2015 Oct; 46(5):335-43. PubMed ID: 26356487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.
    Zhang B; Zou J; Rensing NR; Yang M; Wong M
    Neurobiol Dis; 2015 Aug; 80():70-9. PubMed ID: 26003087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR-related neuropathology in mutant tsc2 zebrafish: Phenotypic, transcriptomic and pharmacological analysis.
    Scheldeman C; Mills JD; Siekierska A; Serra I; Copmans D; Iyer AM; Whalley BJ; Maes J; Jansen AC; Lagae L; Aronica E; de Witte PAM
    Neurobiol Dis; 2017 Dec; 108():225-237. PubMed ID: 28888969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
    Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
    J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H; Dundon TA; Yeung RS
    Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TSC-mTOR signaling pathway regulates the innate inflammatory response.
    Weichhart T; Costantino G; Poglitsch M; Rosner M; Zeyda M; Stuhlmeier KM; Kolbe T; Stulnig TM; Hörl WH; Hengstschläger M; Müller M; Säemann MD
    Immunity; 2008 Oct; 29(4):565-77. PubMed ID: 18848473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
    Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
    Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
    Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
    Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis.
    Zhang MN; Zou LP; Wang YY; Pang LY; Ma SF; Huang LL; Gao Y; Lu Q; Franz DN
    Seizure; 2018 Aug; 60():86-90. PubMed ID: 29929111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K; Borkowska J; Jozwiak S
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
    Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
    Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
    Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
    JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.